Table 1 Demographic data and characteristic findings in patients with retinopathy of prematurity received intravitreal Bevacizumab (IVB) vs. intravitreal Aflibercept (IVA)

GA (weeks)

Mean ± SD

28.2 ± 2

28.2 ± 2

28.7 ± 2.3

0.230†

Median (range)

28 (22 to 34)

28 (22 to 34)

28.5 (25 to 34)

BW (g)

Mean ± SD

1121 ± 314

1119 ± 311

1205 ± 383

0.182†

Median (range)

1060 (550 to 2700)

1050 (550 to 2700)

1190 (730 to 1975)

Time of first treatment

Mean ± SD

59 ± 19

59 ± 19

55 ± 21

0.536¥

Median

57

57

49

Follow up (days)

Mean ± SD

285 ± 255

289 ± 257

143 ± 25

 < 0.001¥

Median

212

217

137

Gender

Male

260

252 (57.2%)

8 (66.7%)

0.362*

Female

193

189 (42.8%)

4 (33.3%)

Twin

Yes

108

107 (24.3%)

1 (8.3%)

0.099*

No

345

334 (75.7%)

11 (91.7%)

O2 therapy

Yes

400

390 (88.4%)

10 (83.3%)

0.054**

No

53

51 (11.6%)

2 (16.7%)

Intubation

Yes

178

176 (40%)

2 (16.7%)

0.130*

No

275

265 (60%)

10 (83.3%)

Transfusion

Yes

257

247 (56%)

10 (83.3%)

0.077*

No

196

194 (44%)

2 (16.7%)

Intraventricular Hemorrhage

Yes

33

31 (7%)

2 (16.7%)

0.096**

No

420

410 (93%)

10 (83.3%)

Sepsis

Yes

177

173 (39.2%)

4 (33.3%)

0.673*

No

276

268 (60.8%)

8 (66.7%)

Phototherapy

Yes

297

293 (66.4%)

4 (33.3%)

 < 0.001*

No

156

148 (33.6%)

8 (66.7%)

Anemia

Yes

46

39 (8.8%)

7 (58.3%)

 < 0.001**

No

407

402 (91.2%)

5 (41.7%)

Acute respiratory distress syndrome

Yes

230

230 (52.2%)

0

 < 0.001*

No

223

21 1(47.8%)

12(100%)

Laterality

Unilateral

17 (3.8%)

17 (3.9%)

0 (0.0%)

 > 0.99**

Bilateral

436 (96.2%)

424 (96.1%)

12 (100.0%)

Eye

OD

443 (49.8%)

431 (49.8%)

12 (50.0%)

0.476¥

OS

446 (50.2%)

434 (50.2%)

12 (50.0%)

Zone pretreatment

1

197 (22.2%)

187 (21.6%)

10 (41.7%)

0.328¥

2

692 (77.8%)

678 (78.4%)

14 (58.3%)

Plus

Yes

885 (99.6%)

861 (99.5%)

24 (100.0%)

0.734¥

No

4 (0.4%)

4 (0.5%)

0 (0.0%)

Neovascularization of iris

Yes

58 (6.5%)

54 (6.2%)

4 (16.7%)

0.331¥

No

831 (93.5%)

811 (93.8%)

20 (83.3%)